205 related articles for article (PubMed ID: 34485083)
21. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
Peterschmitt MJ; Foster MC; Ji AJ; Zajdel MB; Cox GF
Mol Genet Metab; 2023 Mar; 138(3):107527. PubMed ID: 36739645
[TBL] [Abstract][Full Text] [Related]
22. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
[TBL] [Abstract][Full Text] [Related]
23. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
24. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
25. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
[TBL] [Abstract][Full Text] [Related]
26. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
27. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Goker-Alpan O; Watman N; El-Beshlawy A; Kishnani PS; Pedroso ML; Gaemers SJM; Tayag R; Peterschmitt MJ
Blood; 2017 Apr; 129(17):2375-2383. PubMed ID: 28167660
[TBL] [Abstract][Full Text] [Related]
28. Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Lorber J; Niederau C; Carwile JL; Oliveira-Dos-Santos A; Perichon MG; Uslu Cil S; Kishnani PS
Am J Hematol; 2024 Apr; ():. PubMed ID: 38686876
[TBL] [Abstract][Full Text] [Related]
29. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
[TBL] [Abstract][Full Text] [Related]
30. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
[TBL] [Abstract][Full Text] [Related]
31. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
Serrano-Gonzalo I; de Frutos LL; Lahoz-Gil C; Delgado-Mateos F; Fernández-Galán MÁ; Morales-Conejo M; Calle-Gordo MV; Ibarretxe-Gerediaga D; Madinaveitia-Ochoa A; Albarracin-Arraigosa A; Balanzat-Muñoz J; Correcher-Medina P; García-Frade LJ; Hernández-Rivas JM; Labbadia F; López-Dupla JM; Lozano-Almela ML; Mora-Casterá E; Noya-Pereira MS; Ruíz-Guinaldo MÁ; Del Mar Tormo-Díaz M; Vitoria-Miñana I; Arévalo-Vargas I; Andrade-Campos M; Giraldo P
Orphanet J Rare Dis; 2023 Dec; 18(1):390. PubMed ID: 38102667
[TBL] [Abstract][Full Text] [Related]
32. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
[TBL] [Abstract][Full Text] [Related]
33. Glucosylsphingosine (Lyso-Gb
Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
[TBL] [Abstract][Full Text] [Related]
34. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
[TBL] [Abstract][Full Text] [Related]
35. Long-term eliglustat treatment of Gaucher patients over up to 10 years in Vienna.
Stulnig TM
Wien Klin Wochenschr; 2022 Jun; 134(11-12):471-477. PubMed ID: 35412052
[TBL] [Abstract][Full Text] [Related]
36. Recommendations for oral treatment for adult patients with type 1 Gaucher disease.
Torralba-Cabeza MÁ; Morado-Arias M; Pijierro-Amador A; Fernández-Canal MC; Villarrubia-Espinosa J
Rev Clin Esp (Barc); 2022 Jun; ():. PubMed ID: 35676195
[TBL] [Abstract][Full Text] [Related]
37. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
38. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Schiffmann R; Cox TM; Dedieu JF; Gaemers SJM; Hennermann JB; Ida H; Mengel E; Minini P; Mistry P; Musholt PB; Scott D; Sharma J; Peterschmitt MJ
Brain; 2023 Feb; 146(2):461-474. PubMed ID: 36256599
[TBL] [Abstract][Full Text] [Related]
39. A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.
Abrams R; Kaddi CD; Tao M; Leiser RJ; Simoni G; Reali F; Tolsma J; Jasper P; van Rijn Z; Li J; Niesner B; Barrett JS; Marchetti L; Peterschmitt MJ; Azer K; Neves-Zaph S
CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):374-383. PubMed ID: 32558397
[TBL] [Abstract][Full Text] [Related]
40. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
